Actinium Pharmaceuticals saham

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Its clinical programs use its Antibody Warhead Enabling (AWE) technology platform. Its clinical pipeline is led by Antibody Radiation-Conjugates (ARCs). Its lead product candidate, Iomab-B (I-131 apamistamab), is a targeted conditioning agent, which consists of an anti-CD45 monoclonal antibody and the radioisotope Iodine-131 (I-131). Its clinical and preclinical development programs utilize multiple isotopes, including Actinium-225, Iodine-131 and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2 and HER3 for targeted conditioning prior to cell and gene therapies, including bone marrow transplant (BMT) and cancer therapeutics in combination with other therapeutic modalities.